Possible contributions of thyroid hormone replacement to specific behaviors of cancer

Aleck Hercbergs, Paul J. Davis, Hung Yun Lin, Shaker A. Mousa

研究成果: 雜誌貢獻回顧型文獻

3 引文 (Scopus)

摘要

L-Thyroxine (T4) is the principal replacement hormone for patients who have hypothyroidism. Some preclinical and clinical evidence supports the possibility that T4 can at least permissively affect certain features of established cancers and cancer-relevant angiogenesis. Thus, in the occasional patient with hypothyroidism and concomitant cancer, it appears reasonable to consider thyroid hormone replacement exclusively with 3,3′,5-triiodo-L-thyronine (T3). This use of T3 has been shown to be effective and safe in early experience with medical induction of euthyroid hypothyroxinemia in patients with advanced solid tumors.
原文英語
頁(從 - 到)655-659
頁數5
期刊Biomedicine and Pharmacotherapy
84
DOIs
出版狀態已發佈 - 十二月 1 2016

指紋

Thyroid Hormones
Hypothyroidism
Neoplasms
Thyronines
Thyroxine
Hormones

ASJC Scopus subject areas

  • Pharmacology

引用此文

Possible contributions of thyroid hormone replacement to specific behaviors of cancer. / Hercbergs, Aleck; Davis, Paul J.; Lin, Hung Yun; Mousa, Shaker A.

於: Biomedicine and Pharmacotherapy, 卷 84, 01.12.2016, p. 655-659.

研究成果: 雜誌貢獻回顧型文獻

Hercbergs, Aleck ; Davis, Paul J. ; Lin, Hung Yun ; Mousa, Shaker A. / Possible contributions of thyroid hormone replacement to specific behaviors of cancer. 於: Biomedicine and Pharmacotherapy. 2016 ; 卷 84. 頁 655-659.
@article{a441fd71c0f34aae89d7baf756e1bad6,
title = "Possible contributions of thyroid hormone replacement to specific behaviors of cancer",
abstract = "L-Thyroxine (T4) is the principal replacement hormone for patients who have hypothyroidism. Some preclinical and clinical evidence supports the possibility that T4 can at least permissively affect certain features of established cancers and cancer-relevant angiogenesis. Thus, in the occasional patient with hypothyroidism and concomitant cancer, it appears reasonable to consider thyroid hormone replacement exclusively with 3,3′,5-triiodo-L-thyronine (T3). This use of T3 has been shown to be effective and safe in early experience with medical induction of euthyroid hypothyroxinemia in patients with advanced solid tumors.",
keywords = "3,3′,5-Triiodo-L-thyronine (T), Angiogenesis, Apoptosis, Hypothyroidism, L-Thyroxine (T), Thyroid cancer, Tyrosine kinase inhibitor (TKI)",
author = "Aleck Hercbergs and Davis, {Paul J.} and Lin, {Hung Yun} and Mousa, {Shaker A.}",
year = "2016",
month = "12",
day = "1",
doi = "10.1016/j.biopha.2016.09.053",
language = "English",
volume = "84",
pages = "655--659",
journal = "Biomedicine and Pharmacotherapy",
issn = "0753-3322",
publisher = "Elsevier Masson",

}

TY - JOUR

T1 - Possible contributions of thyroid hormone replacement to specific behaviors of cancer

AU - Hercbergs, Aleck

AU - Davis, Paul J.

AU - Lin, Hung Yun

AU - Mousa, Shaker A.

PY - 2016/12/1

Y1 - 2016/12/1

N2 - L-Thyroxine (T4) is the principal replacement hormone for patients who have hypothyroidism. Some preclinical and clinical evidence supports the possibility that T4 can at least permissively affect certain features of established cancers and cancer-relevant angiogenesis. Thus, in the occasional patient with hypothyroidism and concomitant cancer, it appears reasonable to consider thyroid hormone replacement exclusively with 3,3′,5-triiodo-L-thyronine (T3). This use of T3 has been shown to be effective and safe in early experience with medical induction of euthyroid hypothyroxinemia in patients with advanced solid tumors.

AB - L-Thyroxine (T4) is the principal replacement hormone for patients who have hypothyroidism. Some preclinical and clinical evidence supports the possibility that T4 can at least permissively affect certain features of established cancers and cancer-relevant angiogenesis. Thus, in the occasional patient with hypothyroidism and concomitant cancer, it appears reasonable to consider thyroid hormone replacement exclusively with 3,3′,5-triiodo-L-thyronine (T3). This use of T3 has been shown to be effective and safe in early experience with medical induction of euthyroid hypothyroxinemia in patients with advanced solid tumors.

KW - 3,3′,5-Triiodo-L-thyronine (T)

KW - Angiogenesis

KW - Apoptosis

KW - Hypothyroidism

KW - L-Thyroxine (T)

KW - Thyroid cancer

KW - Tyrosine kinase inhibitor (TKI)

UR - http://www.scopus.com/inward/record.url?scp=84988965478&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988965478&partnerID=8YFLogxK

U2 - 10.1016/j.biopha.2016.09.053

DO - 10.1016/j.biopha.2016.09.053

M3 - Review article

C2 - 27697637

AN - SCOPUS:84988965478

VL - 84

SP - 655

EP - 659

JO - Biomedicine and Pharmacotherapy

JF - Biomedicine and Pharmacotherapy

SN - 0753-3322

ER -